Syndax(SNDX) - 2025 Q4 - Annual Results

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – Exhibit 99.1 NEW YORK, NY, February 26, 2026 (GLOBE NEWSWIRE) – Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "We solidified our leaders ...